Metropolis Healthcare announced strong Q2 FY26 results, with revenue increasing by 23% YoY to ₹429 Crore and EBITDA growing by 19% YoY. The company saw growth in patient and test volumes, driven by both B2C and B2B segments. Key strategic initiatives and acquisitions also contributed to the positive performance, boosting the company’s growth momentum.
Financial Performance Q2 FY26
Metropolis Healthcare reported a revenue increase of 23% YoY, reaching ₹429 Crore for the quarter ended September 30, 2025 (Q2FY26). EBITDA grew by 19% YoY to ₹109 Crore, while PAT increased by 13% YoY to ₹53 Crore.
Operational Highlights
Patient and Test Volumes increased by 11% and 12% YoY, respectively. B2C revenue grew by 16% YoY, and B2B revenue increased by 33% YoY. Revenue per Patient (RPP) and Revenue per Test (RPT) increased by 11% and 10% YoY, supported by brand trust, premium offerings, and demand for specialty testing.
Segment Performance
TruHealth wellness and Specialty portfolios recorded strong growth of approximately 24% and 33% YoY, respectively.
North India contributed 19% to the revenue, increasing from 17% in Q1 FY26, and Tier III cities saw revenue growth of 13%.
Acquisition Performance
Core Diagnostics achieved positive PAT within two quarters of acquisition and high single-digit EBITDA margins in Q2. DAPIC (Dehradun) and Scientific Pathology (Agra) continue to outperform.
Dividend Announcement
The Board has approved a dividend of 200% or ₹4 per share.
Source: BSE
